Progressive pulmonary insufficiency and other pulmonary complications of thermal injury.
Progressive pulmonary insufficiency appears to be a universal response to the lung to a variety of injuries which damage the pulmonary-capillary emdothelium. Persistent hyperventilation, unresponsive to the administration of oxygen, is the earliest clinical sign of this complication of trauma and should prompt close monitoring of pulmonary function (measurement of arterial blood gas and pH levels, Vd/Vt A-aDo2, minute ventilation, vital capacity and inspiratory force) to assess the severity of the disease, the need for mechanical ventilatory support and the effectiveness of treatment. Other pulmonary complications of burn injury range from carbon monoxide poisoning and narcotics overdosage in the immediate postburn period through marked hyperventilation directly related to burn size occurring in the absence of significant parenchymal change to later occurring hematogenous and airborne pneumonia. Inhalation injury, a chemical tracheobronchitis which significantly increases the mortality of a given-sized burn, may be present immediately postburn but clinically inapparent for 48-72 hours. 133Xenon lung scans permit early diagnosis of this pulmonary injury and the timely institution of a graduated therapeutic response keyed to the severity of pulmonary disability. Knowledge of the pathogenesis of each of these complications is requisite for the physician caring for burn patients and permits the employment of rational preventive and therapeutic measures.
D002056:Burns / Q000150:complications* / Q000188:drug therapy; D002058:Burns, Electric / Q000150:complications; D002059:Burns, Inhalation / Q000150:complications; D002249:Carbon Monoxide Poisoning / Q000209:etiology; D002404:Catheterization / Q000009:adverse effects; D006801:Humans; D006985:Hyperventilation / Q000139:chemically induced; D008171:Lung Diseases / Q000209:etiology*; D008272:Mafenide / Q000009:adverse effects / Q000627:therapeutic use; D009020:Morphine / Q000009:adverse effects / Q000627:therapeutic use; D011014:Pneumonia / Q000209:etiology; D011654:Pulmonary Edema / Q000209:etiology; D011655:Pulmonary Embolism / Q000209:etiology; D012121:Respiration, Artificial; D012131:Respiratory Insufficiency / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D014136:Tracheitis / Q000209:etiology; D014140:Tracheotomy / Q000009:adverse effects; D014980:Xenon Radioisotopes
D014980:Xenon Radioisotopes; D008272:Mafenide; D009020:Morphine